Revolution Medicines, Inc. Warrant
RVMDW
NASDAQ Global Select8.86
USD
+0.25
- -
Revolution Medicines, Inc. Warrant
RVMDW
(NASDAQ Global Select)
Recent
price
8.86
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Revolution Medicines, Inc. is a late-stage clinical oncology company developing innovative targeted therapies for cancers driven by RAS mutations. The company's research and development efforts are concentrated on a portfolio of RAS(ON) inhibitors, designed to directly inhibit various activated RAS protein variants, either as standalone treatments or in combination with other agents. Key assets in its pipeline include daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor progressing through pivotal Phase 3 clinical trials for metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer, having also received FDA Breakthrough Therapy Designation for pancreatic cancer with KRAS G12 mutations and Orphan Drug Designation. Additionally, elironrasib (RMC-6291), a selective RAS(ON) G12C inhibitor, is in clinical development, with FDA Breakthrough Therapy Designation for KRAS G12C-mutated non-small cell lung cancer. Another important candidate is zoldonrasib (RMC-9805), a selective RAS(ON) G12D inhibitor, also undergoing clinical investigation with plans for a Phase 3 trial in pancreatic cancer. Further pipeline compounds include mutant-selective RAS(ON) inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company also pursues RAS companion inhibitors like RMC-4630 and RMC-5552 for comprehensive treatment strategies. Revolution Medicines has entered into strategic collaborations, including a significant $2 billion funding agreement with Royalty Pharma to advance its RAS(ON) inhibitor programs and a partnership with Iambic Therapeutics leveraging AI in drug discovery. Formed in 2014, Revolution Medicines, Inc. maintains its headquarters in Redwood City, California.
Revolution Medicines, Inc. (NASDAQ:RVMDW) Sees Significant Increase in Short Interest
Revolution Medicines, Inc. (NASDAQ:RVMDW) Short Interest Update